Combined modality therapy for stage IIIMO non-small cell lung cancer. A five-year experience

Madej, Patricia J.; Bitran, Jacob D.; Golomb, Harvey M.; Hoffman, Philip G.; Demeester, Thomas; Desser, Richard K.; Kaul, Raman; Raghavan, V.; Newman, Steven B.; Skosey, Consuelo

doi:10.1002/1097-0142(19840701)54:1<5::aid-cncr2820540103>3.0.co;2-v

Cited by 22 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our series has a large number of adenocarcinoma and large cell carcinoma patients, who have been reported to have a lower long-term survival than squamous cell carcinoma and a higher incidence of brain metastases [32,37]. Three of our nine patients with adenocarcinoma had brain metastases, an observation consistent with other series [65,71]. Prophylactic Cranial Irradiation (PCI) was considered but not instituted by us because of the lack of definite knowledge of the natural history in our study population and the potential long-term side effects of PCI…”

Section: Discussionsupporting

confidence: 67%

Multimodality treatment of non‐small cell lung cancer: Response to cisplatin, VP‐16, and 5‐FU chemotherapy and to surgery and radiation therapy

Sridhar

Thurer

Kim

et al. 1988

Journal of Surgical Oncology

View full text Add to dashboard Cite

Twenty-one patients with unresectable non-small cell lung cancer (NSCLC), 11 with stage III M0, five with malignant pleural effusion, and five with a single resectable metastasis were treated with multimodality therapy. All received two to three cycles of preoperative chemotherapy with a new sequential combination of cisplatin (50 mg/m2 IV X 1) followed by 5-FU infusion (40 mg/m2/hr X 72) and etoposide (80 mg/m2/day X 3). Thirteen of 21 (62%) had a partial response, and three (14%) had a minor response to chemotherapy. Of the 19 who underwent surgical exploration, 17 were confirmed to have NSCLC. Ten patients with NSCLC and one with choriocarcinoma were rendered disease free by resection of the primary tumor and lymph nodes. Six received intra- and/or perioperative interstitial therapy with 125I and/or 192Ir. Another patient was treated with 32P. Postoperative external radiotherapy was administered in 15 patients, and adjuvant chemotherapy was administered in ten. This multimodality therapy was well tolerated, safe, and highly effective, resulting in excellent palliation even in patients with pleural effusion and metastasis. The most promising results were in unresectable stage III M0 with a partial response rate of 82% following neoadjuvant chemotherapy and a complete response rate of 73% after surgery. In this group, median survival has not yet been reached and will exceed 12 months.

show abstract

Section: Discussionsupporting

confidence: 67%

Multimodality treatment of non‐small cell lung cancer: Response to cisplatin, VP‐16, and 5‐FU chemotherapy and to surgery and radiation therapy

Sridhar

Thurer

Kim

et al. 1988

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…The traditional variables for measuring the effect of cancer treatment are survival, tumour response, toxicity, and occasionally physical performance (5,6,9,10,19,29). The methods for measuring these variables are well established and recommended by WHO (33).…”

mentioning

confidence: 99%

Psychosocial well-Being of Patients with Inoperable Non-Small Cell Lung Cancer: The importance of treatment- and disease-related factors

Kaasa¹,

Mastekaasa²

1988

Acta Oncologica

View full text Add to dashboard Cite

Patients with inoperable non-small cell lung cancer, limited disease, were randomized to either chemotherapy (cisplatin and etoposide) or radiotherapy of the thorax. A set of questionnaires, covering 4 areas: psychosocial well-being, medical side effects, physical function, and everyday activity was filled out by 101 patients. The correlations between psychosocial well-being (dependent variable) on the one hand, and medical side effects, physical function, and everyday activity (independent variables) on the other were subjected to multiple regression analysis. No significant correlation was found between psychosocial well-being and chemotherapy-or radiotherapy-related subjective side effects. The disease-related symptoms correlated highly with psychosocial well-being during the observation period. Psychosocial well-being and the independent variables tended to be more strongly correlated during the follow-up period (14-52 weeks) than during the treatment period.

show abstract

“…Although early stage disease is curable by surgical resection (1,2) or radical irradiation (3,4), most patients referred to the radiation oncologist have locally-advanced or metastatic disease and will die of lung cancer. Treatment options for patients with unresectable NSCLC vary widely (5) and range from a watch policy for asymptomatic patients (6) to aggressive, multimodality therapy with curative intent (7,8,9,10,11).…”

Section: Introductionmentioning

confidence: 99%

Non Small Cell Carcinoma of the Lung A Retrospective Study Presented at the 41st Annual Meeting of the Royal Australasian College of Radiologists, September 1990, Perth

Stevens

Firth

1992

Australasian Radiology

View full text Add to dashboard Cite

A retrospective study was undertaken in 1990 of 188 patients with the diagnosis of non small cell carcinoma of the lung referred to the Department of Radiation Oncology in 1984. Most patients (178/188) received a course of radiotherapy. This was definitive in 23, palliative in 148 (primary site in 113, metastases in 16, primary plus metastases in 19) and postoperative in 7. This report is a 5 year followup of the 171 patients treated by radiation alone, to assess factors that influence survival. Tumour histology was 50% squamous, 23% adenocarcinoma, 16% large cell and 4% unspecified, non small cell carcinoma. In 8% no histological diagnosis was obtained. The most common symptoms were cough (44%), dyspnoea (43%), chest pain (37%), haemoptysis (33%) and systemic symptoms (36%). Tumour stage (TNM) was assessed retrospectively as I(5%), II(8%), IIIA(18%), IIIB(22%) and IV(28%). A subgroup of 31 cases (18%) of uncertain staging (I-III) was analysed separately and in 2 cases (1%) no staging information was available. Palliative intent of treatment and poorer performance status were related significantly to increasing stage of disease. The effects of palliative treatment were recorded in 79 cases; in 71 there was a reduction in symptoms. The median survival from diagnosis was 8 months (range < 1-72). Using univariate and multivariate analyses, significant and independent prognostic factors for improved survival were good performance status, absence of systemic symptoms, lower tumour stage and curative intent of treatment (higher radiation dose). However the 5-year survival was only 2%. Long-term survival was associated predominantly with early stage disease but not with the type or intent of treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Combined modality therapy for stage IIIMO non-small cell lung cancer. A five-year experience

Cited by 22 publications

References 14 publications

Multimodality treatment of non‐small cell lung cancer: Response to cisplatin, VP‐16, and 5‐FU chemotherapy and to surgery and radiation therapy

Multimodality treatment of non‐small cell lung cancer: Response to cisplatin, VP‐16, and 5‐FU chemotherapy and to surgery and radiation therapy

Psychosocial well-Being of Patients with Inoperable Non-Small Cell Lung Cancer: The importance of treatment- and disease-related factors

Non Small Cell Carcinoma of the Lung A Retrospective Study Presented at the 41st Annual Meeting of the Royal Australasian College of Radiologists, September 1990, Perth

Contact Info

Product

Resources

About